Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition

Author

A. Aschenbrenner

View on Semantic Scholar

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Explainable Deep Learning Reveals Distributed Neurodegeneration Signatures of Neuropsychiatric Symptoms Across the Alzheimer's Continuum

Neuropsychiatric symptoms (NPS) are increasingly recognized as critical components of the disease progression in Alzheimer's disease (AD), yet their relationship with neurodegeneration remain poorly characterized. We investigated the multivariate relationships between structural MRI (sMRI)-based regional neurodegenerat...

B. Yaghooti, S. Ishrat, H. Le et al. · 0 citations
Open access Jul 2026

The impact of a 12-month randomized exercise intervention on cognitive function and brain volume in adults with down syndrome.

BACKGROUND Adults with Down syndrome (DS) have a high risk for Alzheimer's disease (AD). While exercise improves cognition and brain health in the general population, few long-term studies have evaluated its effects in DS. OBJECTIVE We examined the impact of a 12-month remotely delivered exercise program on cognitive...

L. Ptomey, A. Aschenbrenner, B. Helsel et al. · 0 citations
Open access Aug 2026

Stages of objective memory impairment (SOMI) as a predictor of clinical progression in the A4 study

SOMI’s risk profile in A4 was similar to prior findings in observational cohorts, and provides a low-cost, non-invasive enrichment tool for identifying individuals at risk for early cognitive decline in secondary prevention trials.

Priyanka Kumari, R. Lipton, A. Aschenbrenner et al. · 0 citations
Open access Jul 2026

Remote digital cognitive assessment in a trial‐ready Alzheimer's disease cohort: A scalable approach for early intervention studies

ABSTRACT INTRODUCTION Early detection of cognitive decline in Alzheimer's disease (AD), particularly in preclinical stages, is critical for evaluating therapeutic interventions. Traditional cognitive assessments often require lengthy in‐person visits, and may therefore limit scalability for younger, trial‐ready populat...

A. Aschenbrenner, H. Wilks, Matthew S. Welhaf et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.